- Home
- HRMY vs ECAT Comparison
HRMY vs ECAT Comparison
Compare HRMY & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ECAT
- Stock Information
- Founded
- HRMY 2017
- ECAT 2021
- Country
- HRMY United States
- ECAT United States
- Employees
- HRMY N/A
- ECAT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- HRMY Health Care
- ECAT Finance
- Exchange
- HRMY Nasdaq
- ECAT Nasdaq
- Market Cap
- HRMY 1.6B
- ECAT 1.7B
- IPO Year
- HRMY 2020
- ECAT N/A
- Fundamental
- Price
- HRMY $34.09
- ECAT $15.68
- Analyst Decision
- HRMY Strong Buy
- ECAT
- Analyst Count
- HRMY 8
- ECAT 0
- Target Price
- HRMY $52.88
- ECAT N/A
- AVG Volume (30 Days)
- HRMY 729.2K
- ECAT 278.6K
- Earning Date
- HRMY 05-06-2025
- ECAT 01-01-0001
- Dividend Yield
- HRMY N/A
- ECAT 9.20%
- EPS Growth
- HRMY 13.13
- ECAT N/A
- EPS
- HRMY 2.62
- ECAT 2.39
- Revenue
- HRMY $744,852,000.00
- ECAT N/A
- Revenue This Year
- HRMY $20.06
- ECAT N/A
- Revenue Next Year
- HRMY $18.40
- ECAT N/A
- P/E Ratio
- HRMY $12.76
- ECAT $7.15
- Revenue Growth
- HRMY 20.62
- ECAT N/A
- 52 Week Low
- HRMY $26.47
- ECAT $14.02
- 52 Week High
- HRMY $41.61
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- HRMY 69.87
- ECAT 56.61
- Support Level
- HRMY $29.82
- ECAT $15.48
- Resistance Level
- HRMY $30.61
- ECAT $15.86
- Average True Range (ATR)
- HRMY 1.15
- ECAT 0.24
- MACD
- HRMY 0.71
- ECAT 0.13
- Stochastic Oscillator
- HRMY 98.91
- ECAT 89.16
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.